^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    THE001

    i
    Other names: THE001, DPPG2-TSL-DOX
    Associations

    News

    Trials
    Company:
    Thermosome
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=8, Completed, Thermosome GmbH | Active, not recruiting --> Completed | Trial primary completion date: May 2025 --> Jan 2025
    Trial completion • Trial primary completion date
    |
    THE001 • dexrazoxane
    10ms
    Study of DPPG2-TSL-DOX Combined with Hyperthermia in Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Thermosome GmbH | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> May 2025 | Trial primary completion date: Dec 2024 --> May 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    THE001 • dexrazoxane
    over2years
    Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=9, Recruiting, Thermosome GmbH
    New P1 trial • Metastases
    |
    THE001